Dr GI Joe

Joseph Kumka
  • 4.7 (3)
  • MEDICINE
  • SERIES

I'm Dr. Joseph Kumka, Gastroenterology Fellow, educator, and creator of this podcasts. Whether you're a resident gearing up for the boards, a fellow diving deep into subspecialty topics, or a practicing clinician hungry for high-yield updates—you’re in the right place. Subscribe, engage, and let's raise the bar together. Please not that that these are AI generated podcasts curated from most up to date resources.

Episodes

  1. EPISODE 1

    Motility 1: Manometry Fundamentals — Indications, Caveats, and the Conventional Framework

    Motility 1: Manometry Fundamentals — Indications, Caveats, and the Conventional Framework Episode keywords: esophageal manometry indications, esophageal motility abnormalities, conventional manometry, LES pressure normal values, manometry before Nissen fundoplication, five manometry caveats Episode Summary Before interpreting any manometric tracing, you need the philosophical framework: what the study can and cannot tell you. This episode covers the three core indications for esophageal manometry, five critical interpretive caveats that govern every motility diagnosis, and the conventional four-bucket framework that predates the Chicago Classification. Whether you are reading a board question or ordering a study on a post-EGD dysphagia consult, these principles govern everything downstream. Key Topics When to order esophageal manometry: Three indications — unexplained dysphagia after normal EGD, chest pain after cardiac clearance, and pre-operative evaluation before antireflux surgery. The third indication is the most commonly missed on boards.The five interpretive caveats: (1) Cause of most motility abnormalities is unknown. (2) Abnormalities do not always have physiologic consequences. (3) Symptoms may not respond when the manometric abnormality is corrected. (4) Meeting diagnostic criteria does not establish clinical importance. (5) Diagnosis requires integration of clinical AND manometric data.Conventional four-bucket framework: Inadequate LES relaxation (achalasia), uncoordinated contraction (diffuse esophageal spasm), hypercontraction (nutcracker esophagus), and hypocontraction (ineffective esophageal motility).Normal values: LES basal pressure 10–45 mmHg; LES relaxation residual pressure 8 mmHg above gastric; peristaltic velocity 2–6 cm/sec; distal amplitude 30–180 mmHg.Board Pearls Board trap: Asymptomatic patient with textbook DES pattern on manometry found during pre-op evaluation. The answer is NOT to treat DES — caveats two and four apply. Manometric criteria without clinical relevance do not establish a disorder.High-yield: Manometry before antireflux surgery is a classic board setup. Without it, you risk performing a Nissen on a patient with impaired peristalsis and creating a functional obstruction.

    24 min

  2. EPISODE 2

    Motility 2: High-Resolution Manometry and the Chicago Classification v4.0

    Motility 2: High-Resolution Manometry and the Chicago Classification v4.0Episode keywords: high-resolution manometry, Chicago Classification v4.0, integrated relaxation pressure IRP, distal contractile integral DCI, distal latency, Chicago Classification decision tree, EGJ pressure, Clouse plotEpisode SummaryHigh-resolution manometry replaced 4–8 point sensors with 36 solid-state sensors spaced 1 cm apart, producing color-coded pressure topography Clouse plots that display the entire esophagus simultaneously. This episode teaches the three new metrics — IRP, DCI, and distal latency — and walks through the complete Chicago Classification v4.0 decision tree from the IRP branch point through every diagnosis. The CCv4.0 changes from v3.0 are explicitly board-tested.Key Topics The three HRM metrics:Integrated Relaxation Pressure (IRP): Lowest mean EGJ relaxation pressure over a 4-second window following swallow. Normal: supine median 8,000 (≥20% swallows) → Hypercontractile esophagusNormal IRP + >70% ineffective or ≥50% failed swallows → IEMWhat CCv4.0 changed from v3.0: Positional testing now required (supine AND upright). Clinically inconclusive category introduced for DES, hypercontractile esophagus, IEM, and EGJOO. Symptoms plus confirmatory testing required for diagnosis.Board Pearls Board trap: DCI and DL measure different things. DCI = contraction strength (how hard). DL = contraction timing (how early). DES is a timing disorder, not a strength disorder.High-yield: IRP is always gate one. Ask yourself: is the IRP elevated or normal? Every subsequent decision branches from that answer.

    22 min

  3. EPISODE 3

    Motility 3: Achalasia — Pathophysiology, Etiology, and Diagnosis

    Motility 03: Achalasia — Pathophysiology, Etiology, and Diagnosis Episode keywords: achalasia pathophysiology, ganglion cell degeneration, achalasia subtypes, achalasia diagnosis, pseudoachalasia, Chagas disease esophagus, bird beak sign, achalasia manometry, Type I Type II Type III achalasia Episode Summary Achalasia means "does not relax." The name is the disease. This episode builds from the tissue level — selective inhibitory neuron degeneration — through the HRM subtypes that predict treatment response, to the diagnostic pathway that catches malignancy before it is missed. Understanding the pathophysiology allows you to derive every clinical feature rather than memorize it. Key Topics Core lesion: Degeneration of myenteric (Auerbach) plexus ganglion cells, with preferential loss of inhibitory (nitric oxide-producing) neurons. Cholinergic excitatory neurons are relatively spared, producing unopposed excitation — this is why basal LES pressure rises.Result: Aperistalsis in the esophageal body; incomplete LES relaxation due to lost inhibitory innervation. Neuronal damage can extend to the dorsal motor nucleus of the vagus and vagal fibers.Etiology: Autoimmune (HLA associations, viral triggers including HSV, measles, HPV); emerging Type 2 allergic inflammation hypothesis (eosinophil/mast cell accumulation with association to EoE).Chagas disease: Trypanosoma cruzi infection causes identical ganglion cell loss. Manometrically indistinguishable from primary achalasia. Mandatory serologies for patients from Central/South America.Pseudoachalasia: Malignancy at the EGJ (classically adenocarcinoma) can mimic achalasia by neural invasion or paraneoplastic mechanisms. Red flags: age >55, rapid progression (450, DL 4.5 sec. Worst treatment response.Board Pearls High-yield: Type II → best response. Type III → worst response. This is the most consistently tested point about achalasia subtypes.Board trap: The LES in achalasia traverses easily with gentle endoscopic pressure. If it does NOT pass — think pseudoachalasia, not achalasia. High-yield: Absent gastric air bubble on chest X-ray in a dysphagia patient = elevated IRP preventing swallowed air from reaching the stomach.

    22 min

  4. EPISODE 4

    Motility 4: Achalasia Treatment — Decision Tree and Landmark Trials

    Motility 4: Achalasia Treatment — Decision Tree and Landmark Trials Episode keywords: achalasia treatment, POEM procedure, Heller myotomy, pneumatic dilation achalasia, botulinum toxin achalasia, Boeckxstaens trial NEJM, Werner trial NEJM, Nissen fundoplication achalasia, achalasia GERD after POEM, blown-out myotomy Episode Summary Every achalasia treatment has one goal: reduce LES resting pressure so it no longer obstructs ingested material. No treatment restores peristalsis. All are palliative. This episode covers the treatment hierarchy from pharmacotherapy to POEM, the three landmark RCTs that define the evidence base, and the current ACG and ASGE guideline recommendations — including which treatment is preferred for Type III achalasia. Key Topics Three anchoring principles:All treatments target LES pressure reduction — not esophageal body function.No treatment restores peristalsis. Lost ganglion cells do not return.All therapies deteriorate over time. Patients should anticipate retreatment.Pharmacotherapy (nitrates/calcium channel blockers): Smooth muscle relaxants taken sublingually 10–30 minutes pre-meal. Side effects common. ACG indicates use only when patient cannot undergo definitive therapy AND has failed botulinum toxin. Last resort, not first line.Botulinum toxin injection: Endoscopic injection into LES. Blocks excitatory cholinergic neurons. Remission in ~67% at 6 months. Not durable — most need repeat injections; only ~67% of initial responders maintain remission at one year with repeated injections. Submucosal fibrosis from repeated injections complicates subsequent myotomy. Not a definitive therapy. Use in elderly/infirm patients who cannot tolerate definitive procedures.Pneumatic dilation (PD): 30–40 mm balloons tear LES muscle fibers. Good-to-excellent response in 60–85% after a single session. ~50% require additional therapy within 5 years. Perforation rate 2–5%. Reflux esophagitis in ~5%.Laparoscopic Heller myotomy (LHM): Surgical division of LES muscle under direct visualization. Always paired with partial fundoplication — Dor (anterior) or Toupet (posterior). Nissen (360°) fundoplication is avoided — the aperistaltic esophagus cannot push through a complete wrap. Good-to-excellent response 70–90%. 85% sustained remission at 10 years, 65% at 20 years. Reflux esophagitis ~10%.POEM (per-oral endoscopic myotomy): Submucosal tunnel approach, myotomy performed from inside. Meta-analysis of 2,373 patients: 98% short-term success. Advantage: proximal extension of myotomy for Type III. Disadvantage: no antireflux procedure — GERD symptoms 8.5%, reflux esophagitis 13%, abnormal pH monitoring in 47%. Blown-out myotomy (BOM) described in 30% of POEM patients at 5 years — associated with treatment failure.The landmark RCTs:Boeckxstaens et al., NEJM 2011 Comparison: PD vs LHM (n=201, mean 43 months follow-up) Result: No significant difference. Success rates 86% PD vs 90% LHM at 2 years; 82% vs 84% at 5 years. Established PD and LHM as equivalent in safety and efficacy. Ponds et al., JAMA 2019 Comparison: POEM vs PD (n=126, 2-year primary endpoint) Result: POEM superior — 92% vs 54% at 2 years; 81% vs 40% at 5 years. Reflux esophagitis: 41% POEM vs 7% PD. POEM wins on efficacy; pays a significant GERD price. Werner et al., NEJM 2019 Comparison: POEM vs LHM + Dor fundoplication (n=221, 2-year primary endpoint) Result: Noninferiority met — 83% POEM vs 82% LHM. No significant differences in esophageal function or quality of life. Reflux esophagitis: 44% POEM vs 29% LHM at 2 years; 41% vs 31% at 5 years. POEM and LHM equivalent in efficacy; POEM carries higher reflux burden without fundoplication. Guideline recommendations:ACG: LHM, PD, and POEM are all comparable for Type I and II. POEM preferred for Type III.ASGE: Tailored myotomy (POEM or LHM) preferred for Type III. Patients should be counseled on POEM's higher GERD risk.Board Pearls Board trap: POEM versus LHM for Type I/II — equivalent efficacy, but POEM carries significantly higher GERD burden because there is no fundoplication.High-yield: Nissen fundoplication is contraindicated in achalasia. Partial wrap (Dor or Toupet) is the rule when peristalsis is impaired. High-yield: Botulinum toxin is not a definitive therapy. If a board option offers it as first-line — it is a distractor.

    21 min

  5. EPISODE 5

    Motility 5: EGJ Outflow Obstruction and FLIP

    Motility 5: EGJ Outflow Obstruction and FLIP Episode keywords: EGJ outflow obstruction EGJOO, FLIP panometry, functional luminal imaging probe, EGJ distensibility index, Dallas Consensus FLIP classification, upright IRP, EGJOO differential diagnosis, opioids elevated IRP, timed barium esophagram Episode Summary EGJOO is the most over-diagnosed entity in motility. The Chicago Classification v3.0 was too permissive; CCv4.0 significantly tightened the criteria and introduced the concept that manometric EGJOO is always clinically inconclusive without confirmatory testing. This episode covers the full differential, the new criteria, and the FLIP — the tool that tells you what manometry cannot: whether the EGJ actually opens when you push something through it. Key Topics EGJOO pattern: Elevated IRP + preserved peristalsis. Not achalasia (which requires absent peristalsis), but something is obstructing EGJ outflow.The differential:Early or evolving achalasiaEosinophilic esophagitis (fibrosis impairing EGJ distensibility)Malignancy at the EGJHiatal hernia artifact (especially paraesophageal hernias)Opioid useObesity (increased intra-abdominal fat)Spurious finding of no clinical importanceCCv4.0 EGJOO criteria (all required for manometric diagnosis):Median IRP above ULN in BOTH supine AND upright positionsSome preserved peristalsis≥20% of swallows show increased intrabolus pressureEGJOO is ALWAYS clinically inconclusive on manometry alone. A clinically relevant diagnosis additionally requires: symptoms of dysphagia and/or chest pain, PLUS confirmatory testing (timed barium esophagram showing delayed emptying, or FLIP showing reduced distensibility).Upright IRP pearl: Upright IRP >12 mmHg identifies radiographically confirmed EGJOO with 98% sensitivity. If upright IRP is ≤12 mmHg, true obstruction is unlikely.FLIP — functional luminal imaging probe: Impedance planimetry catheter with 16 paired electrodes and a pressure sensor. Measures cross-sectional area using impedance data. Produces a real-time 3D image of the esophagus during balloon distension.EGJ Distensibility Index (DI): Narrowest cross-sectional area ÷ intraluminal pressure at that segment. At 60 mL fill volume: Normal EGJ opening (NEO): DI ≥2.0 mm²/mmHg AND max diameter ≥16 mmReduced EGJ opening (REO): DI 40 mmHg), or diminished (pressure 40 mmHg).Dallas Consensus classification grid (EGJ opening × contractile response):NEO + Normal → Normal (major motility disorder highly unlikely)REO + Normal → Mechanical obstruction patternREO + Spastic → Spastic obstruction (Type III achalasia variant)REO + Absent → Non-spastic obstruction (Types I/II achalasia)NEO + Absent/Diminished → Hypocontractility patternNEO + Spastic → Possible spasm patternBoard Pearls Board trap: Patient on chronic opioids with manometric EGJOO — do not diagnose achalasia. Rule out opioid-induced IRP elevation first.High-yield: Normal FLIP panometry (NEO + normal contractile response) makes a major motility disorder highly unlikely. Most experts still require HRM to diagnose achalasia, but normal FLIP is strongly reassuring.

    23 min

  6. EPISODE 6

    Motility 6: Distal Esophageal Spasm and Hypercontractile Esophagus

    Motility 6: Distal Esophageal Spasm and Hypercontractile Esophagus Episode keywords: distal esophageal spasm HRM, corkscrew esophagus, premature contractions DL, nutcracker esophagus vs jackhammer esophagus, hypercontractile esophagus DCI, Chicago Classification DES criteria, Pandolfino 2011 distal latency, contraction front velocity, non-cardiac chest pain motility Episode Summary Both DES and hypercontractile esophagus live on the normal-IRP side of the Chicago Classification. Both are rare, both have frustrating treatment responses, and both are full of terminology traps that boards specifically exploit. This episode covers the shift from simultaneous contractions to premature contractions as the defining criterion for DES, the Pandolfino 2011 study that drove that change, and the critical distinction between nutcracker esophagus (amplitude-based, conventional manometry) and hypercontractile/jackhammer esophagus (DCI-based, HRM). Key Topics DES — clinical picture: Episodic dysphagia with chest pain. Barium swallow: corkscrew esophagus (tertiary contractions). Presentation mimics cardiac chest pain.The criterion change — simultaneous contractions to premature contractions:Old criterion (conventional manometry): Simultaneous contractions with contraction front velocity >6–9 cm/sec.New criterion (HRM, CCv4.0): Premature contractions with DL 2 SD above normal. Amplitude-based. Associated with non-cardiac chest pain and GERD. Clinical importance disputed.Hypercontractile/jackhammer esophagus (CCv3.0, CCv4.0): DCI >8,000 mmHg·cm·sec in ≥20% of swallows. Volume-based (integrates amplitude × duration × length). These are not the same entity."Nutcracker esophagus" is not a CCv4.0 diagnosis. The term is fading.CCv4.0 hypercontractile esophagus criteria (all required):Normal IRPDCI >8,000 mmHg·cm·sec in ≥20% of swallowsSymptoms of dysphagia and/or chest painSecondary causes excluded (opioids, GERD, EoE)Hypercontractile treatment: Mirrors DES. Smooth muscle relaxants, neuromodulators, botulinum toxin, POEM in refractory cases.Board Pearls Board trap: HRM shows rapid contraction front velocity with normal DL. Is this DES? No. CCv4.0 requires short DL (180 mmHg. Is this hypercontractile esophagus? Not necessarily — you need the DCI, not peak amplitude. Amplitude ≠ DCI. High-yield: If IRP is elevated and there are premature contractions — that is Type III achalasia, not DES. The IRP is the branch point.

    15 min

  7. EPISODE 7

    Motility 7: IEM, Opioid Effects, and Non-Cardiac Chest Pain

    Motility 7: IEM, Opioid Effects, and Non-Cardiac Chest Pain Episode keywords: ineffective esophageal motility IEM, scleroderma esophagus manometry, absent contractility, fundoplication IEM, opioid esophageal motility, opioid elevated IRP, non-cardiac chest pain algorithm, functional chest pain neuromodulators, Chicago Classification IEM criteria, visceral hypersensitivity esophagus Episode Summary The final episode closes the loop on the normal-IRP side of the Chicago Classification and ties the entire series together. Esophageal hypocontraction — from the scleroderma esophagus to IEM — has a critical intersection with surgical planning: weak peristalsis and a Nissen fundoplication is a mistake that manometry is specifically designed to prevent. The episode also covers opioid-induced esophageal dysfunction (the great mimicker of every motility diagnosis) and the evidence-based stepwise approach to non-cardiac chest pain. Key Topics Scleroderma esophagus: Fibrosis and vascular obliteration damage esophageal smooth muscle. Manometric hypocontraction in ~80% of scleroderma patients. Weak clearance + hypotensive LES = severe GERD with impaired acid clearance. Not scleroderma-specific — identical findings in mixed connective tissue disease, RA, SLE, diabetes, amyloidosis, alcoholism, myxedema, MS, and longstanding GERD. "Scleroderma esophagus" should be reserved for patients with confirmed scleroderma.IEM — CCv4.0 criteria:>70% of swallows ineffective (failed: DCI 5 cm in 20 mmHg isobaric contour with DCI ≥450)OR ≥50% of swallows outright failed (DCI 100)Note: CCv3.0 required ≥50% failed or weak. CCv4.0 made this more stringent.100% failed peristalsis = Absent contractility — a separate, more severe diagnosis.IEM and fundoplication — the critical board intersection:If a patient has IEM and you perform a Nissen (360° wrap), the weakly peristaltic esophagus cannot generate sufficient pressure to push a bolus through the tight wrap → post-operative dysphagia.If IEM is present: use partial fundoplication (Toupet 270° posterior or Dor 180° anterior), or avoid fundoplication altogether.This is the same principle as in achalasia — peristaltic impairment is a contraindication to complete wraps.Opioid-induced esophageal dysfunction:Opioids can mimic nearly every HRM diagnosis: elevated IRP (EGJOO, achalasia-like), elevated DCI (hypercontractile), short DL (DES, Type III-like).Opioids are in the explicit EGJOO differential and should be considered in any elevated-IRP pattern.Rule: Before diagnosing ANY primary motility disorder on HRM, check the medication list for opioids. If opioids are present — discontinue (if possible) and repeat the study.Non-cardiac chest pain — the stepwise algorithm:Exclude cardiac, thoracic, and pancreaticobiliary causes first. Cardiology evaluation if needed.Check for alarm symptoms (dysphagia, weight loss, bleeding) → endoscopy if present.If no alarm features: check for typical GERD symptoms → endoscopy → pH monitoring if endoscopy normal.No alarm, no typical GERD symptoms → double-dose PPI trial for 2 months. Relief = GERD confirmed.PPI failure → esophageal manometry.Manometry shows motility disorder → treat per disorder-specific guidelines, add neuromodulator.Normal manometry → functional chest pain. Treat with neuromodulator (TCA, trazodone, SSRI) + cognitive behavioral therapy.Data: Up to 70% of NCCP patients have typical GERD symptoms. Abnormal pH monitoring in 40–60%. ~80% of NCCP patients with abnormal pH or erosive esophagitis achieve pain relief with PPIs. Fewer than 30% have abnormal motility studies.Board Pearls High-yield: Manometry before antireflux surgery exists specifically to catch IEM. Nissen + IEM = post-operative dysphagia. Know this cold.Board trap: Opioid-using patient with HRM showing elevated IRP, premature contractions, and elevated DCI — do not diagnose achalasia + DES + hypercontractile esophagus. The answer is opioid-induced dysmotility. High-yield: Non-cardiac chest pain algorithm — cardiac exclusion FIRST, then GERD evaluation, then PPI trial, then manometry. Jumping directly to manometry is wrong if the cardiac workup has not been completed.

    22 min
  • 7 Episodes

Ratings & Reviews

4.7
out of 5
3 Ratings

About

I'm Dr. Joseph Kumka, Gastroenterology Fellow, educator, and creator of this podcasts. Whether you're a resident gearing up for the boards, a fellow diving deep into subspecialty topics, or a practicing clinician hungry for high-yield updates—you’re in the right place. Subscribe, engage, and let's raise the bar together. Please not that that these are AI generated podcasts curated from most up to date resources.

Information

  • Creator
    Joseph Kumka
  • Years Active
    2025 - 2026
  • Episodes
    7
  • Rating
    Clean
  • Copyright
    © 2025